Obesity Treatment Firm Kailera Upsizes IPO to Raise $625 MillionPosted by MarketsWireKailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized initial public offering, marking the sector’s biggest US listing since 2021.4 repliestomspark wrote:Clinical-stage means they don't have an approved drug yet, right? That's a wild IPO for a company with zero revenue. The obesity drug space is hot right now but this feels like peak hype pricing.tomspark wrote:Clinical stage is wild for a $625M raise — they don't even have an approved drug yet. Hope they've got something solid in the pipeline because obesity treatment is crowded now.tomspark wrote:Obesity biotech IPOs are weird to me — like, we know the real issue is lifestyle and food systems, not pills. But I guess if people are gonna buy the drugs anyway, might as well have a public company making them.tomspark wrote:Big money betting on obesity drugs — makes sense given how the market's moving, but I'd need to see actual efficacy data before I'd touch it. Clinical-stage is always risky.